Harbour Biomed and Yantai Lannacheng Biotechnology announced a long‑term strategic collaboration to co‑develop next‑generation radionuclide‑drug conjugates (RDCs) for cancer treatment. The partnership combines Harbour’s discovery capabilities with Lannacheng’s radiochemistry and development infrastructure in China. The deal aims to accelerate RDC preclinical optimization and clinical entry, leveraging targeted radionuclide payloads to expand therapeutic options for hard‑to‑treat tumors. Partnerships pairing biologics discovery with radiopharmaceutical expertise are increasingly common as companies pursue precision targeted radiotherapy. Observers will look for details on lead assets, IND timelines and how the companies plan GMP manufacturing and regulatory strategy for radioconjugates.